P64k is found in vaccine formulations as a Neisseria meningitidis high molecular weight protein for the prevention of meningococcal infections. P64k is an outer membrane lipoamide dehydrogenase that is used as an available immunological carrier as it is highly immunogenic in animals. And CimaVax EGF, a P64k conjugated cancer vaccine is approved by Cube.
Cimavax-EGF is a therapeutic cancer vaccine designed to produce neutralizing antibodies against EGF that inhibit the fusion of EGF and EGFR. CimaVax-EGF is the first class of therapeutic lung cancer vaccine that chemically compromises yeast-derived human EGF, and is linked with the P64K protein of N. meningitidis produced by Escherichia coli (E. coli), and an immunoadjuvant (aluminium hydroxide or Contained ISA51). The drug was developed by CIMAB, and Bioven has exclusive rights to CimaVax-EGF and Biotech Pharmaceuticals in the U.S. and China, respectively.
Yaohai Bio-Pharma offers One-Stop CDMO Solution for N. meningitidis P64k Protein
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
